Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US8153397B2 · kind B2 · utility
3Cited by
10References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 27, 2009 |
| Grant date | Apr 10, 2012 |
| Priority date | — |
| Expiry date | Apr 27, 2029 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/842
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to the construction, expression, and purification of synthetic or recombinant light chain (LC) botulinum neurotoxin genes from all botulinum neurotoxin serotypes. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product is stable and proteolytically active. Methods of using the products of the invention are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.